CHICAGO, May 8, 2018 /PRNewswire/ -- Linden Capital Partners ("Linden"), a Chicago-basedhealthcare private equity firm, today announced the closing of its fourth private equity fund, Linden Capital Partners IV ("Fund IV"), with $1.5 billion of limited partner commitments.
Similar to Linden's prior funds,
Since its inaugural fund in 2005, Linden has pursued an investment strategy in private equity focused on adding significant value to middle market healthcare companies in the services, medical products, specialty distribution, and pharmaceutical sectors, among others. Linden expanded its resources throughout the deployment phase of its third fund, including the addition of four new investment professionals, five new operating partners, and an additional member to the firm's finance team.
Linden Capital Partners closed its first fund of $200 million in 2005, its second fund of $375 million in 2010, and its third fund of $750 million in 2015.
Kirkland & Ellis LLP served as legal advisors and Park Hill Group LLC served as placement advisor.
About Linden Capital Partners
Linden Capital Partners is a Chicago-based private equity firm focused exclusively on leveraged buyouts in the healthcare industry. Linden's strategy is based upon three elements: i) healthcare specialization, ii) integrated private equity and operating expertise, and iii) strategic relationships with large corporations. Linden invests in middle market platforms in the medical products, specialty distribution, pharmaceutical, and services segments of healthcare. For more information, please visit www.lindenllc.com.
View original content:http://www.prnewswire.com/news-releases/linden-capital-partners-raises-1-5-billion-for-fund-iv-300644956.html
SOURCE Linden Capital Partners
Subscribe to our Free Newsletters!
Sleep paralysis is a condition where one feels unable to move (paralysis) or speak either when ...
Summers days are long, hot and sweaty, and can leave you feeling de-hydrated and tired. Read on to ...
Fosnetupitant and Palonosetron (a fixed antiemetic combination) injection was approved by FDA in ...View All